Cuadra, Merliza A.

HRN: 27-62-92  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/14/2025
CO-AMOXICLAV 625MG (TAB)
08/14/2025
08/20/2025
PO
625mg
Bid
Cs
Checking Initial Appropriateness 

 Indication:  Prophylaxis    Type of Infection:  Prophylaxis    Compliance to guidelines: Compliant To Guidelines